PRELUDE THERAPEUTICS INC Lease Obligation Incurred
PRELUDE THERAPEUTICS INC (PRLD) reported Lease Obligation Incurred of $382.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-16.
Discontinued › Cash Flow
us-gaap:CapitalLeaseObligationsIncurred · last filed 2021-03-16
- PRELUDE THERAPEUTICS INC lease obligation incurred for fiscal 2019 was $382.00K.
| Period end | Lease Obligation Incurred 12 month |
|---|---|
| 2019-12-31 | $382.00K 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |